China Shineway Pharmaceutical Group Ltd. is an investment holding company, which engages in the research and development, manufacturing, and trading of Chinese pharmaceutical products. The company is headquartered in Shijiazhuang, Hebei and currently employs 2,867 full-time employees. The company went IPO on 2004-12-02. The Company’s product dosage forms include injections, soft capsules, granules, traditional Chinese medicine (TCM) granules, oral products and other dosage forms. The Company’s products include Qing Kai Ling Injection, Shen Mai Injection, Wu Fu Xin Nao Qing Soft Capsule, Qing Kai Ling Soft Capsule, Huamoyan Granule, Compound Licorice Tablet and other products, applied to influenza, cardio-cerebrovascular, respiratory system and other disease fields. The firm operates its business in mainland China and Hong Kong markets.
China Shineway Pharmaceutical Group Limited 的關鍵財務報表是什麼?
根據最新的財務報表(Form-10K),China Shineway Pharmaceutical Group Limited 的總資產為 $10,041,淨利潤為 $840
CSWYY 的關鍵財務比率是什麼?
China Shineway Pharmaceutical Group Limited 的流動比率為 3.9,淨利潤率為 22.23,每股銷售為 $5。
China Shineway Pharmaceutical Group Limited 的收入按細分市場或地理位置如何劃分?
China Shineway Pharmaceutical Group Limited 最大收入來源為 Injections,在最近的收益報告中收入為 1,374,777,459。就地區而言,China including Hong Kong 是 China Shineway Pharmaceutical Group Limited 的主要市場,收入為 4,096,244,475。
China Shineway Pharmaceutical Group Limited 是否盈利?
是的,根據最新的財務報表,China Shineway Pharmaceutical Group Limited 的淨利潤為 $840
China Shineway Pharmaceutical Group Limited 有負債嗎?
是的,China Shineway Pharmaceutical Group Limited 的負債為 2,574
China Shineway Pharmaceutical Group Limited 的流通股有多少?
China Shineway Pharmaceutical Group Limited 的總流通股為 827